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Abstract
Background: For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy
may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty (decisional
conflict), which may be lessened with patient decision aids (PDA). PRIMETIME (ISRCTN 41579286) is a UK-led
biomarker-directed study evaluating omission of adjuvant radiotherapy in breast cancer; an embedded Study Within
A Trial (SWAT) investigated whether PDA reduces decisional conflict using a cluster stepped-wedge trial design.
Methods: PDA diagrams and a video explaining risks and benefits of radiotherapy were developed in close
collaboration between patient advocates and PRIMETIME trialists. The SWAT used a cluster stepped-wedge trial
design, where each cluster represented the radiotherapy centre and referring peripheral centres. All clusters began
in the standard information group (patient information and diagrams) and were randomised to cross-over to the
enhanced information group (standard information plus video) at 2, 4 or 6 months. Primary endpoint was the
decisional conflict scale (0–100, higher scores indicating greater conflict) which was assessed on an individual
participant level. Multilevel mixed effects models used a random effect for cluster and a fixed effect for each step to
adjust for calendar time and clustering. Robust standard errors were also adjusted for the clustering effect.
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Results: Five hundred twenty-one evaluable questionnaires were returned from 809 eligible patients (64%) in 24
clusters between April 2018 and October 2019. Mean decisional conflict scores in the standard group (N = 184)
were 10.88 (SD 11.82) and 8.99 (SD 11.82) in the enhanced group (N = 337), with no statistically significant
difference [mean difference − 1.78, 95%CI − 3.82–0.25, p = 0.09]. Compliance with patient information and
diagrams was high in both groups although in the enhanced group only 121/337 (36%) reported watching the
video.
Conclusion: The low levels of decisional conflict in PRIMETIME are reassuring and may reflect the high-quality
information provision, such that not everyone required the video. This reinforces the importance of working with
patients as partners in clinical trials especially in the development of patient-centred information and decision aids.
Keywords: Breast, Cancer, Decisional-conflict, De-escalation, Oncology, Radiotherapy, Cluster, Stepped-wedge,
SWAT
Introduction
Adjuvant radiotherapy following breast conserving sur-
gery (BCS) plays an important role in the treatment of
early breast cancer. The absolute benefit of radiotherapy
is dependent on the individual patient’s prognosis.
Radiotherapy carries risk. For some patients with very
low-risk of local relapse, radiotherapy risks may out-
weigh the benefits, and for these patients, risk adaptation
of treatment to omit radiotherapy may be preferable,
with this hypothesis being under evaluation in several
studies [1–5]. Treatment de-escalation may increase pa-
tient uncertainty (decisional conflict) in relation to their
care pathway. Uncertainty may be increased if insuffi-
cient information is provided. Supplementing standard
patient information material with patient decision aids
(PDA) has been hypothesised to reduce decisional con-
flict. PDA are tools helping patients understand treat-
ment risks and benefits, consider values placed on the
risk-benefit ratio and participate with clinicians in decid-
ing treatment options. Testing of the hypothesis that
PDA reduce decisional conflict requires evaluation in
the context of a clinical trial, for example via a ‘Study
Within A Trial’ (SWAT). A SWAT is a research study
embedded within a clinical trial enabling assessment of
different ways of designing, conducting, analysing and
evaluating components of the research conduct [6].
PRIMETIME is a UK-led biomarker-directed interven-
tional cohort study aiming to identify a group of breast
cancer patients who can safely avoid adjuvant radiother-
apy following BCS [1]. A SWAT was conducted within
PRIMETIME to identify whether PDA reduced deci-
sional conflict in patients considering treatment de-
escalation. In this paper we report the development of
the PRIMETIME PDA and SWAT execution.
Methods
Context for SWAT
Details of PRIMETIME have been published previously
[1]. The biomarker IHC4+C (incorporating Ki-67) is
used to determine the patient’s recurrence risk [7]. Pa-
tients predicted to be at very-low risk are directed to
avoid radiotherapy, and patients at low, intermediate or
high-risk are directed to receive radiotherapy as per
standard of care [1]. Patients both accepting and declin-
ing the recommendation are followed up. Patients were
able to consent to the SWAT even if they subsequently
declined PRIMETIME.
PDA development
PDA were developed in close collaboration with PRIM
ETIME patient advocates and designed to be used in
conjunction with patient information sheets. Diagrams
were designed to explain the risks and benefits of radio-
therapy using natural frequency formats (numerical
values expressed as event rates in groups with and with-
out the intervention). They also explained the risks of
recurrence in the different risk groups and compared re-
currence risk in patients receiving and not receiving
radiotherapy in the low-risk group (Fig. 1a, b). Diagrams
were designed to be used in the clinic consultation with
the healthcare professional and patient present.
Building on the written information it was considered
that radiotherapy risks and benefits could also be pre-
sented in a different format such as a video to be
watched by patients independently. A working group
consisting of patient advocates and PRIMETIME Trial
Management Group members, together with a series of
patient focus groups established content to be included
in the PDA video. The PDA were designed according to
criteria outlined by the International Patient Decision
Aid Standards [8].
SWAT development and execution
All patients being approached for PRIMETIME were eli-
gible for the SWAT; all sites participated. The SWAT
was implemented using a cluster stepped-wedge trial de-
sign. The stepped-wedge design consists of the sequen-
tial implementation of an intervention to participants
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grouped within clusters over a number of time periods
[9]. Cluster randomisation ensured all patients within a
single site received uniform information for specified
time periods. The stepped-wedge design enabled all site
clusters to receive the intervention sooner than in a
parallel-group cluster randomised trial, where all clusters
could be given access to the intervention at the end of
the study. Each site cluster was defined as the radiother-
apy centre and its non-treating referral sites. All sites
began in the standard group which included patient
Fig. 1 a Patient information diagrams explaining the risk of distant recurrence in patients at very low, low and intermediate risk. b Patient
information diagrams explaining the risk of local recurrence in patients who do and do not receive radiotherapy in the very low risk group
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information sheet and diagrams; at pre-specified time-
points, site clusters switched to the enhanced group,
which included patient information sheet, diagrams, and
video. The intervention (video) pertained to both the
cluster and individual participant level.
After patients decided whether or not they wished to
participate in PRIMETIME, patients were asked to
complete a questionnaire (Appendix figure 1 and 2).
Questionnaires assessed decisional conflict using a vali-
dated tool and patients were asked to indicate their
highest level of education. Of note, the outcome was
assessed at individual patient level. Questionnaires
(paper-based) were distributed to patients in the clinic.
Return of the questionnaire indicated patient consent to
the sub-study.
Site clusters were allocated, via minimisation, to switch
from standard to enhanced information at 2, 4 or 6
months. Minimisation was performed manually using a
single balancing factor of prior recruitment to the IM-
PORT HIGH [10] and or FAST FORWARD [11] breast
radiotherapy trials, as an indication of trial research ex-
perience. Minimisation was performed at the Institute of
Cancer Research Clinical Trials and Statistics Unit. Each
site cluster was informed of their cross-over date via
email after their first patient had consented to the
SWAT. Access to the video was restricted until 1 week
before cross-over at which point an email containing a
web link to the video and DVDs were sent to the centres
for patients without internet access.
The SWAT primary endpoint was the decisional con-
flict score (0–100, with greater scores indicating more
decisional conflict) [12] which was assessed on an indi-
vidual participant level. Secondary endpoints were ac-
ceptance of entry into PRIMETIME and acceptance of
the recommended treatment within PRIMETIME. The
decisional conflict subscale scores of uncertainty, in-
formed, values clarity, support and effective decision
were also assessed.
Statistical methods
The SWAT target sample size was 264 patients based on
three steps in the cluster stepped-wedge trial design (at
2, 4 and 6months) of 33 site clusters (11 per step), with
2 patients/site cluster/2-month period. Of note, the
number of participants within each cluster and number
of clusters was unknown as the SWAT was planned
within a newly recruiting trial. Equal cluster sizes were
assumed. There is no published definition of a clinically
significant reduction in decisional conflict; two studies
conducted in similar populations to PRIMETIME found
effect sizes around 0.40, with standard deviations for the
total decisional conflict scale score ranging from 11 to
25 [13, 14]. There are no published data on the intra-
class correlation (ICC) for the decisional conflict scale.
Assuming α = 0.05, 264 patients from 33 site clusters
would have ≥ 80% power across the full range of ICC
values (0–1) to detect a 10-point difference in total score
for the decisional conflict scale (effect size = 0.55, stand-
ard deviation = 18). Recruitment was extended beyond
the original accrual target until all site clusters had
switched as per protocol with cluster randomised
stepped-wedge trials.
Analyses were conducted on an intention-to-treat
basis, with questionnaires analysed according to the
cross-over date regardless of whether patients reported
having watched the video. Of note, each patient com-
pleted a single questionnaire. Multilevel mixed effects
models used a random effect for cluster and a fixed ef-
fect for each step to adjust for calendar time and cluster-
ing. Robust standard errors were also adjusted for the
clustering effect [15, 16]. A linear regression model was
used for the decisional conflict scale and subscales; an
estimate of the difference in mean scores pre- and post-
video-implementation was obtained (with 95% confi-
dence interval, CI), and groups were compared using the
z-test. Secondary endpoints (acceptance of entry into
PRIMETIME and recommended treatment) used logistic
regression and were reported as odds ratios (OR) with
95%CI. Additionally, total decisional conflict scores were
dichotomised using a cut-off of ≥ 25 to define ‘clinically
significant’ decisional conflict [17, 18], and groups were
compared using logistic regression as for the secondary
endpoints. Exploratory analyses including age and edu-
cation in the models assessed associations with deci-
sional conflict. The ICC value for the overall decisional
conflict score was estimated from the primary endpoint
model.
There is no published guidance for dealing with miss-
ing data in the decisional conflict scale, and so EORTC
guidance for quality of life measures was used [19],
whereby missing items are imputed from the mean of
completed items providing ≥ 50% of the questions are
completed.
Analyses used Stata version 14 based on a data snap-
shot taken on 25 October 2019. The SWAT was ap-
proved by the East of England Research Ethics
Committee on 22nd February 2018 (16/EE/0305). PRIM
ETIME (ISRCTN 41579286) is funded by Cancer Re-
search UK (C17918/A20015). The SWAT was registered
in the SWAT store - MRC Hubs for Trials Methodology
Research (SWAT 56) [20].
Results
PDA video development
Focus groups determined the video should build on the
existing patient information sheets and diagrams, pro-
viding the same information but in a different format.
Patient advocates felt providing additional information
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would not only be overwhelming, but unethical to
have differing content available to participants. Spe-
cific themes from existing materials the advocates
advised highlighting in the video included; risks of
recurrence, benefits and side effects of radiotherapy
and lack of clear survival benefit from radiotherapy
for low-risk breast cancer. Also, the possibility of
treating any subsequent local recurrences radically
with surgery +/− radiotherapy was highlighted. It
was also felt important to highlight that patients not
receiving radiotherapy would undergo extra mammo-
grams from years 6 to 10 and therefore be moni-
tored more intensively compared with standard of
care.
A script was developed using a question-based for-
mat, including an explanation of why the PRIMET
IME study was being run, what was needed to calcu-
late the patient’s risk and how we weigh up the risks
and benefits of radiotherapy (Appendix table 1). The
video was developed in collaboration with Eyewitness
productions, who also produced the interactive
graphics explaining recurrence risk based on the dia-
grams (Appendix figure 3). The side effects of radio-
therapy were explained similarly (Appendix figure 4).
The video is available at https://www.icr.ac.uk/
primetime.
SWAT execution
Five hundred twenty-one evaluable questionnaires were
returned from 809 eligible patients (64% return rate)
[Fig. 2] in 24 clusters (Table 1) between April 2018 and
October 2019. Median ages (interquartile range) of those
patients who did and did not consent to the SWAT were
69 (65–72) and 68 (64–72) respectively. With regard to
questionnaire return, 184 questionnaires were returned
by the standard group and 337 returned by the en-
hanced group. Median age was similar between the
standard and enhanced groups [70 versus 68 years re-
spectively], as was education level (Table 2). There were
no differences in distribution of age or education level
over the time period of the study. All patients in both
groups read the patient information sheet. However,
compliance with the additional material varied; of those
with available data, 135 (73%) and 290 (86%) reported
using the diagrams in the standard and enhanced groups
respectively. In the enhanced group, 121 (36%) reported
watching the video, 172 (51%) did not and 44 (13%) had
missing data. There were no differences in age and edu-
cation level between those who did and did not watch
the video.
Mean decisional conflict scores in the standard group
(N = 184) were 10.88 (SD 11.82) and 8.99 (SD 11.82) in
the enhanced group (N = 337). There was no statistically
significant difference in decisional conflict scores
Fig. 2 Consort—‘participant flow diagram’
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between the groups [estimated mean difference − 1.78,
95% CI − 3.82–0.25, p = 0.09; effect size 0.08]. A nega-
tive value indicates a reduction in mean scores in the en-
hanced compared with the standard group. There were
no apparent differences between decisional conflict
across time between the two groups.
Clinically significant decisional conflict was reported
in fewer patients in the enhanced group (62/377, 16%)
compared with 42/184 (23%) in the standard group, al-
though this difference was not statistically significant
[OR 0.67 (0.40–1.11), p = 0.12].
Table 1 Summary of questionnaires returned from eligible patients per site cluster in the standard and enhanced groups in the
PRIMETIME SWAT (eligible patients in brackets)
White box: Cluster receiving standard information. Pink box: Cluster receiving enhanced information. Number represents the number of patients returning
questionnaires in the standard and enhanced groups per site cluster, and numbers in brackets represent the eligible patients in each timepoint. 0 months is
baseline. *This questionnaire was returned later than originally planned
Bhattacharya et al. Trials          (2021) 22:397 Page 6 of 10
The majority of patients who returned questionnaires
in the SWAT had consented to PRIMETIME [179/184
(97%) and 326/337 (97%) patients in the standard and
enhanced groups respectively] (Fig. 2), with no statisti-
cally significant difference between groups [OR = 0.95
(0.17–5.22), p = 0.95]. For patients with available data,
163 (93%) patients in the standard group opted for their
recommended treatment and 13 (7%) did not; in the en-
hanced group, 300 (96%) patients opted for their recom-
mended treatment and 13 (4%) did not [Fig. 2]. There
was no statistically significant difference in patients
accepting the recommended treatment in PRIMETIME
according to whether they were in the standard or en-
hanced groups [OR = 1.17 (0.59–2.29), p = 0.66].
There was no significant association between either
age or education level and decisional conflict scores
when allowing for the effects of the standard and en-
hanced groups and time to cross-over (Appendix table
2). There were also no significant differences in subscale
scores between the groups (Appendix table 3). The ICC
for total decisional conflict score was estimated to be
0.03.
Discussion
PDA were designed in close collaboration with patient
advocates to help patients consider the risks and benefits
of adjuvant breast radiotherapy. The PRIMETIME
SWAT investigated whether the addition of a video to
patient information sheets and diagrams could reduce
decisional conflict. We found that absolute levels of de-
cisional conflict were low on average in both the stand-
ard and enhanced groups, with no significant reduction
in decisional conflict following video implementation
and that less than half of the patients reported watching
the video. There was no statistically significant difference
in the acceptance of PRIMETIME entry or recom-
mended treatment between the two groups.
Development of the PDA was primarily patient-led
with advocates identifying important concepts in breast
cancer radiotherapy which needed to be communicated
to patients. This was facilitated by a series of focus
groups where patients and healthcare professionals
established the most important concepts for patients to
understand when considering a de-escalation trial such
as PRIMETIME. These concepts fed into the compre-
hensive PDA development process. Patient advocates
also identified as a challenge being able to clearly explain
concepts such as risks of recurrence. In general, patients
may be able to more accurately perceive risk when nu-
merical values are used. Using natural frequency formats
and expressing probabilities as an event rate out of 100
or 1000 patients can help improve understanding [21].
Natural frequency formats were therefore used through-
out the PRIMETIME PDA to aid patient understanding.
PDA were designed relatively simply and cheaply to be
easily usable for patients both within and independent of
the clinic consultation. Although the SWAT preceded
the COVID-19 pandemic, there has now been an accel-
eration into a practice of fewer face-to-face consulta-
tions, increase in telephone/video consultations and
remote consent. This makes the use of PDA and videos
particularly timely to help patients and clinicians in the
informed consent process.
The PDA were tested using the SWAT concept em-
bedded within the PRIMETIME study across UK cancer
centres. This enabled questions regarding decisional
conflict in this population to be answered in parallel
with the primary question of the main trial which was to
identify a group of patients with low-risk breast cancer
who can safely avoid radiotherapy. However, it was
found the response rate for this SWAT was only 64%.
Of note, there were no significant differences in age be-
tween those patients who consented to or declined the
Table 2 Summary of baseline characteristics and information
use in patients in the standard and enhanced groups
Standard group
N = 184 (%)
Enhanced group
N = 337 (%)
Age (median, IQR) 70 (66-73) 68 (65-72)
Age categories:
60–64 40 (22) 77 (23)
65–69 52 (28) 121 (36)
70–74 55 (30) 97 (29)
≥ 75 37 (20) 42 (12)
Education level*
PG degree/degree 43 (24) 83 (27)
A-level/HND 28 (15) 45 (14)
School cert/O-level 59 (32) 118 (38)
No formal education 50 (27) 66 (21)
Patients reading PIS
Yes 176 (96) 331 (98)
No 0 0
Missing 8 (4) 6 (2)
Patients looking at
diagrams 135 (73) 290 (86)
Yes 35 (19) 38 (11)
No 14 (8) 9 (3)
Missing




*Data regarding education level missing for 4 patients in standard group and
25 patients in the enhanced group. Percentages calculated using all
available data
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SWAT (age was the only baseline characteristic available
for comparison). An important consideration is that this
SWAT encompassed a broader patient group than that
entered into the main trial, including those who declined
entry into the main trial. Although trial guidance was
that all patients who were eligible for PRIMETIME were
to be offered entry to the SWAT, it may have been that
sites were not able to offer the SWAT for example due
to capacity issues. Patients declining the SWAT may
have different characteristics or levels of decisional con-
flict. It is therefore important that sites are supported to
approach these patients so they are given the opportun-
ity to participate in other studies albeit with a separate
consent process. Also, it was found that data were miss-
ing within the SWAT including whether patients
watched the video. Missing data can be a challenge in
trials but possibly even more so in a SWAT.
Regarding the numbers of questionnaires returned in
each group, 184 questionnaires were returned from 268
eligible patients (69%) and 337 questionnaires were
returned from 541 eligible patients (62%), in the stand-
ard and enhanced groups respectively. The reason for
the greater number of questionnaires returned in the en-
hanced group may be explained by SWAT recruitment
improving over time meaning that recruitment may co-
incidentally improve whilst sites were in the enhanced
group. It should also be noted that a requirement of a
stepped-wedge trial is that all sites must remain open
until every site has crossed over. This may result in
some sites spending extended periods of time in the en-
hanced group. The mean decisional conflict scores were
not statistically significantly different between the
groups, although the proportion of patients with ‘clinic-
ally significant’ decisional conflict appeared to be mar-
ginally higher in the standard compared with the
enhanced group. The low average decisional conflict
scores in the standard group may have made further
substantial reductions unlikely [mean scores were 10.88
(SD 11.82) and 8.99 (SD 11.82) in the standard and en-
hanced groups respectively, with decisional conflict be-
ing scored on a scale of 0–100]. Of note, levels of
decisional conflict in the PRIMETIME SWAT are simi-
lar to those in the IBIS II trial which investigated the use
of a PDA in a randomised controlled trial of an aroma-
tase inhibitor in patients at high risk of breast cancer
(prevention group) and patients with DCIS (treatment
group) [13.2 (SD = 14.5)] [14]. Most cancer clinical trials
provide written information and do not usually include
pictorial diagrams; incorporation of the diagrams was an
intervention in itself and may have contributed to the
low decisional conflict scores in the standard group. Fur-
thermore, the SWAT may have been underpowered to
detect a more modest effect size in terms of reduction in
decisional conflict. However, with no guidelines available
for defining clinically significant reduction in decisional
conflict, the choice of statistical assumptions for design-
ing this type of study has to be consensus led from the
trialists.
Study limitations
With respect to study limitations, only 36% of patients
in the enhanced group reported having watched the
video (data missing for 13%). The standard information
may have been of sufficient quality to fulfil the informa-
tion needs of these patients. Some patients may not have
been made aware of the video or preferred not to have
watched it at a potentially stressful time around their
diagnosis. In addition, the SWAT was restricted to pa-
tients who were able to read and understand English in-
dependently in order to complete the questionnaire,
although this is not an eligibility criteria restriction for
the main study.
It is also possible that patients’ decisional conflict may
have reduced over time irrespective of the video inter-
vention as researchers at the centres became more expe-
rienced at discussing the trial with patients and other
trial procedures—termed a ‘learning curve’. Further-
more, in a stepped-wedge trial where all centres begin in
the control group, this learning curve would dispropor-
tionately adversely affect the control compared with the
intervention group. A sensitivity analysis of the primary
endpoint excluding patients who had returned question-
naires in the first two months of the sub-study being
open in their centre was done, but this did not affect the
results. Research teams at sites may have adapted the
way they described the study after having watched the
video themselves, although this was not measured.
Implementing a new intervention mid-way through a
trial may have been a challenge for sites and an alterna-
tive would have been to use a parallel-group cluster ran-
domised trial design whereby clusters are allocated
which type of information to use throughout the dur-
ation of the trial (albeit with the option of all clusters
getting access to the intervention at the end of the
study).
Clinical implications
PDA were designed in collaboration with patients to en-
hance information for those considering treatment de-
escalation. The SWAT concept enabled these to be
tested in an efficient and economic manner. Levels of
decisional conflict were low on average in patients re-
ceiving standard information incorporating diagrams.
The diagrams alone may have resulted in low decisional
conflict scores in the standard group, such that further
substantial reductions would be unlikely. De-escalation
trials can be a challenge to conduct and recruit to, albeit
acceptance to PRIMETIME is high. In general, patients
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may perceive that ‘more is better’ and clinicians may
practice ‘better safe than sorry’ [22]. This emphasises the
importance of patient-led information delivery to ensure
patients understand and feel comfortable with the trial
especially in the era of treatment de-escalation.
Conclusion
The low levels of decisional conflict in PRIMETIME are
reassuring and may reflect the high-quality information
provision including diagrams designed by patients for
patients in collaboration with researchers, such that not
everyone required the video. This reinforces the import-
ance of working with patients as partners in clinical tri-
als especially in the development of patient-centred
information and decision aids. Furthermore, in an era of
increasing use of virtual clinic appointments and con-
sent, videos are an invaluable resource to help patients
make informed decisions regarding breast radiotherapy.
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